BRAF--a new player in hematological neoplasms

Marcin M Machnicki; Tomasz Stoklosa

doi:10.1016/j.bcmd.2014.01.001

BRAF--a new player in hematological neoplasms

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):77-83. doi: 10.1016/j.bcmd.2014.01.001. Epub 2014 Feb 2.

Authors

Marcin M Machnicki¹, Tomasz Stoklosa²

Affiliations

¹ Department of Immunology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland.
² Department of Immunology, Medical University of Warsaw, Banacha 1A, 02-097 Warsaw, Poland. Electronic address: tomasz.stoklosa@wum.edu.pl.

PMID: 24495477
DOI: 10.1016/j.bcmd.2014.01.001

Abstract

BRAF oncogenic kinase has become a target for specific therapy in oncology. Genetic characterization of a predominant V600E mutation in melanoma, thyroid cancer, and other tumors became a focus for developing specific inhibitors, such as vemurafenib or dabrafenib. Our knowledge regarding the role of mutated BRAF in hematological malignancies has grown quickly as a result of new genetic techniques such as next-generation sequencing. This review summarizes current knowledge regarding the role of BRAF in lymphoid and myeloid neoplasms, with a focus on hairy-cell leukemia, Langerhans cell histiocytosis, and Erdheim-Chester disease.

Keywords: BRAF kinase; Histiocytosis; Leukemia; V600E mutation.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Hematologic Neoplasms / drug therapy
Hematologic Neoplasms / genetics*
Hematologic Neoplasms / metabolism*
Humans
Molecular Targeted Therapy
Mutation
Proto-Oncogene Proteins B-raf / antagonists & inhibitors
Proto-Oncogene Proteins B-raf / genetics*
Proto-Oncogene Proteins B-raf / metabolism*

Substances

BRAF protein, human
Proto-Oncogene Proteins B-raf